Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04639310 · ClinicalTrials.gov registry record · Phase 3
XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy
A Phase 3 study, sponsored by Xenon Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 8
- Enrollment target
NCT04639310: Clinical Trial Phase 3 study, sponsored by Xenon Pharmaceuticals.
NCT04639310 is a Phase 3 study that was terminated before completion, run by Xenon Pharmaceuticals. The registered enrollment target is 8 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04639310, a Phase 3 study, was terminated before completion, sponsored by Xenon Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 8 participants
- Enrollment target
Study Summary
To investigate the potential antiseizure effects of adjunctive XEN496 (ezogabine) compared with placebo in children with KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE).
Primary Outcome
Parent/caregiver seizure diary record will be used to assess frequency, type and duration of seizure activity
Interventions
- DRUG Placebo
- DRUG XEN496
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2021-03-29 |
| Est. Completion | 2023-05-16 |
| Phase | Phase 3 |
Why NCT04639310 stopped before completion
NCT04639310 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04639310 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04639310 about?
NCT04639310 is a clinical study titled "XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy". To investigate the potential antiseizure effects of adjunctive XEN496 (ezogabine) compared with placebo in children with KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE).
What is the current status of trial NCT04639310?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 8 participants. The study started on 2021-03-29. Estimated completion is 2023-05-16.
What interventions are being tested in trial NCT04639310?
The interventions under investigation include: Placebo (DRUG), XEN496 (DRUG).
Who is sponsoring clinical trial NCT04639310?
This trial is sponsored by Xenon Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04639310's enrollment target sits among peer trials
8 1993rd of 2000 higher than 6 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI